|Videos|December 20, 2022
First-Line Treatment of mNSCLC with Combination Immunotherapy plus Chemotherapy and Key Data Updates from POSEIDON
Author(s)Edward B. Garon, MD, MS
In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.
Advertisement
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
2
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
3
Proton Therapy Does Not Improve Survival in Advanced HCC Trial
4
CD47-Targeted Evorpacept Shows Durable Responses in HER2+ Gastric Cancer
5